Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Research
Biotech
Merck KGaA drops pipeline asset from SpringWorks buyout
Merck KGaA is no longer pursuing clinical-stage candidates obtained through its acquisition of SpringWorks, which centered on approved drugs.
Will Maddox
Mar 5, 2026 4:33pm
Tenaya, Alnylam ink collab to find gene targets for cardio drugs
Mar 5, 2026 10:56am
ARPA-H launches $158M effort for first lymphatic meds
Mar 4, 2026 8:55am
Theravance halves head count, ends R&D work after ph. 3 fail
Mar 3, 2026 12:08pm
How GLP-1s help the heart relax: study
Mar 2, 2026 7:01pm
Lilly debuts Nvidia supercomputer with fanfare and focus
Feb 27, 2026 1:37pm
